Comparative Pharmacology
Head-to-head clinical analysis: DEXAIR versus HYDELTRA TBA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAIR versus HYDELTRA TBA.
DEXAIR vs HYDELTRA-TBA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEXAIR (dexamethasone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., cytokines, prostaglandins). It also inhibits leukocyte infiltration and reduces capillary permeability.
Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene transcription to suppress inflammation, immune response, and adrenal function.
Inhalation: 2 inhalations (80 mcg each) twice daily, maximum 640 mcg/day.
20-40 mg intramuscularly every 3 weeks; for intra-articular use: 20-40 mg per large joint, 10-20 mg per medium joint, 4-10 mg per small joint.
None Documented
None Documented
Terminal elimination half-life: 3.0-4.5 hours in adults with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Plasma t1/2 ~2.5-3.5 hours. Duration of adrenal suppression may persist for 24-48 hours.
Renal (urinary): ~65-75% as unchanged drug and metabolites; biliary/fecal: ~20-30% as metabolites; less than 10% unchanged in bile.
Primarily renal (80-90% as inactive metabolites and unchanged drug). Biliary excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid